Document Detail

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
MedLine Citation:
PMID:  20942865     Owner:  NLM     Status:  In-Process    
The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules. This prospective trial differs from previous melphalan-prednisone (MP) vs. MPT trials by treatment dosing, duration, routine anticoagulation, and permission for a crossover. Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60). Primary endpoint was treatment response and toxicities following 4 and 8 cycles of therapy. Secondary endpoints were disease-free (DFS) and overall survival (OS). Overall, MPT-treated patients were younger (median 69 yr vs. 72 yr; P=0.016) and had a higher incidence of renal impairment (RI, 19% vs. 7%, respectively; P=0.057). After 4 cycles of treatment (n=115), there were more partial responses or better in the MPT arm than in the MP arm (57.9% vs. 37.5%; P=0.030). However, DFS and OS were not significantly different between the arms after a median of 23 months follow-up (median OS 26.0 vs. 28.0 months, P=0.655; DFS 21.0 vs. 14.0 months, P=0.342, respectively). Crossover to MPT was required in 11 patients, 57% of whom responded to treatment. A higher rate of grade 3-4 infections was observed in the MPT arm compared with the MP arm (22.4% vs. 7.0%; P=0.033). However, none of these infections were associated with febrile neutropenia. Death within the first 3 months was observed more frequently in the MP arm (n=8, 14.0%) than in the MPT arm (n=2, 3.4%; P=0.053). Long-term discontinuation and dose reduction rates were also analyzed (MPT: 15.5% vs. MP: 5.3%; P=0.072). Although patients treated with MPT were relatively younger and had more frequent RI, better responses and less early mortality were observed in all age groups despite more frequent discontinuation.
Meral Beksac; Rauf Haznedar; Tulin Firatli-Tuglular; Hakan Ozdogu; Ismet Aydogdu; Nahide Konuk; Gulsan Sucak; Işik Kaygusuz; Sema Karakus; Emin Kaya; Ridvan Ali; Zafer Gulbas; Gulsum Ozet; Hakan Goker; Levent Undar
Related Documents :
12560225 - Efficacy and safety of rituximab in type ii mixed cryoglobulinemia.
9558165 - Slicc/acr damage index in afro-caribbean patients with systemic lupus erythematosus: ch...
1137255 - Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: c...
11260275 - Combined prednisolone and intravenous immunoglobulin treatment for acquired factor viii...
17221055 - Temporomandibular joint arthrocententesis: evaluation of results and review of the lite...
22841165 - Effect of preoperative renal function on long-term survival after cardiac surgery.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-22
Journal Detail:
Title:  European journal of haematology     Volume:  86     ISSN:  1600-0609     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  16-22     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons A/S.
Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97...
Next Document:  Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclopho...